{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 40,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide lists five levers, though the title mentions six.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/12",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.96,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "list",
      "text": "Preemptive Prototype Approach to Addressing SARS-CoV-2 Variants: Generating data for variant-encoding vaccine candidates to support platform approach to emerging SARS-CoV-2 variants",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5918d463-d11a-4de8-855c-fdb6e009e0ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.96,
        "x": 0.02,
        "y": 0.24
      },
      "kind": "list",
      "text": "Global Clinical Program to Generate Data and Support Label Expansion to Additional Populations: Positive safety and efficacy data reported in children aged 5 to <12; Children cohorts 2-5 years and 6 months to 2 years of age: data expected late Q4 2021 or early Q1 2022; Global Phase 2/3 trial in healthy pregnant women ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d157600-041c-4471-9803-c4439d428160",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.12
      },
      "kind": "list",
      "text": "Increased Manufacturing Capacity: Expect to manufacture 2.7 bn to 3 bn doses by end of 2021; Global COVID-19 vaccine supply chain and manufacturing network with more than 20 manufacturing facilities across four continents",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d6fffad-6c70-499f-8a32-35b075264dcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.72
      },
      "kind": "list",
      "text": "Optimize Formulations to Further Simplify Access Worldwide: FDA and EMA authorized storage of current vaccine for up to 9 months at -90 to -60 °C; New formulation with further simplified handling and optimized storage – up to 10 weeks at 2 to 8 °C – approved by EC, following positive opinion from EMA CHMP",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3232804-e440-4828-9cd6-c0fd2e1f8455",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.84
      },
      "kind": "list",
      "text": "Addressing Waning Immune Reponses: Multiple trials ongoing to address need for booster dose of BNT162b2, including a 10,000-participant efficacy study demonstrating 95.6% relative vaccine efficacy against disease after booster dose during period when Delta variant was prevalent strain",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db3c88c9-ba11-4e49-a7c9-b0fe3ee95152",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.96,
        "x": 0.02,
        "y": 0.4
      },
      "kind": "list",
      "text": "Regulatory Advancement Across All Geographies: BLA approval in the United States for BNT162b2 to prevent COVID-19 in individuals 16 and older; Booster dose: U.S. FDA authorization for emergency use in individuals 65 and older, individuals 18-64 at high risk of severe COVID-19, or with frequent exposure, and for third dose in severely immunocompromised individuals; EC approval in individuals ≥ 18 years of age and for third dose in severely immunocompromised people following positive opinion from EMA CHMP; Label extension: Submitted for variation of CMA to EMA in children 5 to <12; EUA granted in U.S. for children 5 to <12",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfd37058-d58c-4b56-b81a-cefb9cb2be5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Continued Progress Across Six Key Levers to Expand COVID-19 Vaccine Reach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76a9080a-e8f2-494a-b304-41e53f860c05",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "3ef0a596-8c25-4f98-9ce3-ac572ab324b0",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation provides key messages and takeaways on COVID-19 vaccine reach and therapeutic modalities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "e3928016-4f85-43ef-b051-6dae022547eb",
      "evidence": "The presentation provides a clear logic chain of performance and pipeline growth",
      "position": 0,
      "objective": "To demonstrate BioNTech's strong performance and pipeline expansion",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}